2-PROPEN-1-ONE, 1-(2-FLUOROPHENYL)-3-(4-HYDROXYPHENYL)-, O-(2-(DIMETHYLAMINO)ETHYL)OXIME, (1Z,2E)-
Chronic Pain
SanofiSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
101 Active assets in the Chronic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-TRAMADOL EMS | Phase 4 | BBB |
LIDOCAINE National and Kapodistrian University of Athens | Phase 4 | BBB |
METHADONE Cari Health Inc. | Phase 4 | BBB |
FENTANYL Aga Khan University | Phase 4 | BBB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Stanford University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
2-PROPEN-1-ONE, 1-(2-FLUOROPHENYL)-3-(4-HYDROXYPHENYL)-, O-(2-(DIMETHYLAMINO)ETHYL)OXIME, (1Z,2E)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →